With a median follow up of 4.7 years, TBS emerged as a highly significant predictor of fracture.
← all excerpts
Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score.
1
—
—